

SCIENTIFIC REPORTS

OPEN Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1

Published online: 22 January 2019

Edwin Garcia¹, Annette Hayden¹, Charles Birts¹, Edward Britton², Connor Rogerson², Christopher W. Bleaney², Andrew Cowie¹, Karen Pickard¹, Massimiliano Mellone¹, Clarisa Choh¹, Mathieu Derouet¹, Patrick Duriez¹, Fergus Noble¹, Michael J. White¹, John N. Primrose¹, Jonathan C. Strefford¹, Matthew Rose-Zerilli¹, Gareth J. Thomas¹, Yeng Ang², Andrew D. Sharrocks², Rebecca C. Fitzgerald³, Timothy J. Underwood¹ & the OCCAMS consortium*

Correction to: *Scientific Reports* <https://doi.org/10.1038/srep32417>, published online 07 September 2016

This Article contains errors.

After publication of the Article it has come to our attention that the cell stocks used for ATAC-seq analyses may have been contaminated. We therefore revalidated the original stocks using STR profiling and repeated ATAC-seq analysis using these new stocks.

Based on their contributions to the repeat experiments, two new authors, Connor Rogerson and Christopher W. Bleaney, should be included in the author list.

As a result, in the Acknowledgements section,

“The authors gratefully acknowledge funding from Cancer Research UK for the OCCAMS/ICGC project, MRC Clinician Scientist Grant for TJU, MCRC CRUK clinical training fellowship for EB, Maria Secrier for her advice regarding the WGS data and Southampton ECMC Tissue Bank and the Southampton Computation modelling group for access to the IRIDIS4 computer resource.”

should read:

“The authors gratefully acknowledge funding from Cancer Research UK for the OCCAMS/ICGC project, MRC Clinician Scientist Grant for TJU, MCRC CRUK clinical training fellowship for EB and CWB, MCRC CRUK non-clinical training fellowship for CR. Maria Secrier for her advice regarding the WGS data and Southampton ECMC Tissue Bank and the Southampton Computation modelling group for access to the IRIDIS4 computer resource.”

Furthermore, in the Author Contributions section,

¹Faculty of Medicine, University of Southampton, Southampton General Hospital, Mailpoint 801, South Academic Block, Tremona Road, Southampton, SO16 6YD, United Kingdom. ²Faculty of Biology, Medicine and Health, Oxford Road, University of Manchester, Manchester, M13 9PT, UK. ³MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, United Kingdom. *A comprehensive list of consortium members appears at the end of the paper. Correspondence and requests for materials should be addressed to T.J.U. (email: T.J.Underwood@soton.ac.uk)

“Performed the experiments: E.G., A.H., C.B., A.C., K.P., M.M., C.C., M.D., P.D. and M.J.W. Contributed reagent/materials: J.C.S. and R.C.F., OCCAMS Contributed with analysis tools: E.G., E.B., J.C.S., M.R.Z., A.D.S. and R.C.F. OCCAMS prepare figures: E.G., A.H., C.C., E.B. and T.J.U.”

should read:

“Performed the experiments: EG, AH, CB, CWB, AC, KP, MM, CC, MD, PD, MJW. Contributed reagent/materials: JCS, RCF, OCCAMS. Contributed with analysis tools: EG, EB, CR, JCS, MRZ, ADS, RCF, OCCAMS. Prepared figures: EG, AH, CC, EB, CR, TJU.”

The outcome of this analysis differs slightly from the one reported in the Article.

In Materials and Methods section, under the subheading “ATAC-seq data analysis”,

“A 500 bp window around the summit of the top 50,000 regions identified by MACS2 were analysed for differential accessibility using Cufflinks²⁵. Normalised cleavage events across the differentially accessible regions were then counted using HOMER³⁸. Heatmaps were plotted with the tool GENE-E (BROAD Institute) De novo motif discovery was carried out in HOMER³⁸ with flag `-cpg` for background normalisation. Data are deposited with ArrayExpress (Accession number E-MTAB-4209).”

should read:

“A 500 bp window around the summit of the top 50,000 regions identified by MACS2 were analysed for differential accessibility using Cufflinks²⁵. Regions that showed a significant ($p < 0.05$) linear 5 fold change in ATAC-seq signal were taken forward for further analyses. Normalised cleavage events across the differentially accessible regions were then counted using HOMER³⁸. Heatmaps were plotted with the tool GENE-E (BROAD Institute). De novo motif discovery was carried out in HOMER³⁸ with flag `-cpg` for background normalisation. Data are deposited with ArrayExpress (Accession numbers E-MTAB-4209 and E-MTAB-6720).”

In Results section, under the subheading “ATAC-seq analysis of the open accessible chromatin landscape of MFD-1 cells”,

“We identified two classes of regions, which showed >3 fold changes in chromatin accessibility which were either higher (open in MFD-1) or lower (open in HET1A) in MFD-1 compared to HET1A cells (Fig. 4b).”

should read:

“We identified two classes of regions, which showed >5 fold changes in chromatin accessibility which were either higher (open in MFD-1) or lower (open in HET1A) in MFD-1 compared to HET1A cells (Figure 4b).”

In the same section,

“For example, the *KAT6A* promoter is more open specifically in MFD-1 cells (Fig. 4c, top) although at other loci, exemplified by the *KRT8* gene, the chromatin associated with the TSS is more open in both MFD-1 and OE33 cancer cell lines compared to HET1A cells (Fig. 4c, bottom).”

should read:

“For example, the *BBOX1* promoter is more open specifically in MFD-1 cells (Figure 4c, top) although at other loci, exemplified by the *KRT8* gene, the chromatin associated with the TSS is more open in both MFD-1 and OE33 cancer cell lines compared to HET1A cells (Figure 4c, bottom).”

and,

“In regions of chromatin activated in MFD1 cells, motifs recognised by CTCF, NFY, Meis3 and Nrf2 were identified (Fig. 4d, top). In contrast, in chromatin regions showing reduced accessibility in MFD-1 cells and hence potentially lower activity, a different set of motifs were identified with AP-1 figuring most prominently among these (Fig. 4d, bottom). Thus regulatory events controlled by different transcription factors are likely important determinants of the gene expression programmes in MFD-1 and HET1A cells. Interestingly, Gene Ontology analysis of the genes associated with the regulatory regions exhibiting differential accessibility (either increased or decreased) in MFD-1 cells showed enrichments for a large number of terms associated with cancer, including several epithelial cancers and GI tract neoplasms (Fig. 4e).”

should read:

“In regions of chromatin activated in MFD1 cells, motifs recognised by FRA1 (AP1), GRHL1, ELF3 and TEAD3 were identified (Figure 4d, top). In contrast, in chromatin regions showing reduced accessibility in MFD-1 cells and hence potentially lower activity, a different set of motifs were identified with JunB (AP-1) figuring most

prominently among these (Figure 4d, bottom). Thus regulatory events controlled by different transcription factors are likely important determinants of the gene expression programmes in MFD-1 and HET1A cells. Interestingly, Gene Ontology analysis of the genes associated with the regulatory regions exhibiting increased accessibility in MFD-1 cells showed enrichments for a large number of terms associated with cancer, including several epithelial cancers and GI tract neoplasms (Figure 4e).”

In the legend of Figure 4,

“(a) RNA-seq analysis (top) of genes differentially expressed to higher levels in MFD-1 compared to OE33 cells (>3 fold change; P-value < 0.01). Each column represents one biological replicate. Data are row Z-normalised. The corresponding ATAC-seq signal in a 700 bp window around the TSS (–500 to +200 bp) of this cohort of genes in each cell line is shown as a boxplot of cut count densities (bottom). ***P-value < 0.05 (2×10^{-13}). (b) ATAC-seq analysis showing the cut counts in regions showing differential accessibility (>3 fold; P-value < 0.05) between MFD-1 and HET1A cells. Data are shown for MFD-1, OE33 and HET1A cells and grouped according to being more open in MFD-1 or HET1A cells. (c) UCSC genome browser tracks showing ATAC-seq cleavage data associated with the KAT6A (top) and KRT8 (bottom) loci in HET1A, OE33 and MFD-1 cells. Regions of open chromatin associated with the TSS (arrows) are boxed. (d) De novo motif discovery of transcription factor binding sites over-represented in the regions that are either open in MFD-1 cells (top) or HET1A cells (bottom). (e) GO term analysis of genes associated with a TSS showing changes (>3 fold) in open chromatin in MFD-1 compared to HET1A cells. The most highly significant terms associated with disease Ontology are shown.”

should read:

“(a) RNA-seq analysis (top) of genes differentially expressed to higher levels in MFD-1 compared to OE33 cells (>3 fold change; P-value < 0.01). Each column represents one biological replicate. Data are row Z-normalised. The corresponding ATAC-seq signal in a 1000 bp window around the TSS (–500 to +500 bp) of this cohort of genes in each cell line is shown as a boxplot of cut count densities (bottom). **** = P-value < 0.0001. (b) ATAC-seq analysis showing the cut counts in regions showing differential accessibility (>5 fold; P-value < 0.05) between MFD-1 and HET1A cells. Data are shown for MFD-1, OE33 and HET1A cells and grouped according to being more open in MFD-1 or HET1A cells. (c) UCSC genome browser tracks showing ATAC-seq cleavage data associated with the *BBOX1* (top) and *KRT8* (bottom) loci in HET1A, OE33 and MFD-1 cells. Regions of open chromatin associated with the TSS (arrows) are boxed. (d) De novo motif discovery of transcription factor binding sites over-represented in the regions that are either open in MFD-1 cells (top) or HET1A cells (bottom). (e) IPA GO term analysis of genes associated with a TSS showing changes (>5 fold) in open chromatin in MFD-1 compared to HET1A cells. The most highly significant terms associated with disease ontology are shown.”

An updated version of Figure 4 based on the repeated experiments is shown below as Figure 1.

The overall conclusions of this Article are unaffected by the changes. The authors apologise for the errors.




Figure 1. Open chromatin regions in MFD-1 cells. **(a)** RNA-seq analysis (top) of genes differentially expressed to higher levels in MFD-1 compared to OE33 cells (>3 fold change; P-value < 0.01). Each column represents one biological replicate. Data are row Z-normalised. The corresponding ATAC-seq signal in a 1000 bp window around the TSS (−500 to +500 bp) of this cohort of genes in each cell line is shown as a boxplot of cut count densities (bottom). **** = P-value < 0.0001. **(b)** ATAC-seq analysis showing the cut counts in regions showing differential accessibility (>5 fold; P-value < 0.05) between MFD-1 and HET1A cells. Data are shown for MFD-1, OE33 and HET1A cells and grouped according to being more open in MFD-1 or HET1A cells. **(c)** UCSC genome browser tracks showing ATAC-seq cleavage data associated with the *BBOX1* (top) and *KRT8* (bottom) loci in HET1A, OE33 and MFD-1 cells. Regions of open chromatin associated with the TSS (arrows) are boxed. **(d)** *De novo* motif discovery of transcription factor binding sites over-represented in the regions that are either open in MFD-1 cells (top) or HET1A cells (bottom). **(e)** IPA GO term analysis of genes associated with a TSS showing changes (>5 fold) in open chromatin in MFD-1 compared to HET1A cells. The most highly significant terms associated with disease ontology are shown.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

Consortia the OCCAMS consortium

Shona MacRae³, Nicola Grehan³, Zarah Abdullahi³, Rachel de la Rue³, Ayesha Noorani³, Rachael Fels Elliott³, Nadeera de Silva³, Jan Bornschein³, Maria O'Donovan³, Gianmarco Contino³, Tsun-Po Yang³, Hamza Chettouh³, Jason Crawte³, Barbara Nutzinger³, Paul A. W. Edwards³, Laura Smith³, Ahmad Miremadi⁴, Shalini Malhotra⁴, Alison Cluroe⁴, Richard Hardwick⁵, Jim Davies⁶, Hugo Ford⁷, David Gilligan⁷, Peter Safranek⁷, Andy Hindmarsh⁷, Vijayendran Sujendran⁷, Nick Carroll⁷, Richard Turkington⁸, Stephen J. Hayes^{9,15}, Yeng Ang^{9,10,32}, Shaun R. Preston¹¹, Sarah Oakes¹¹, Izhar Bagwan¹¹, Vicki Save¹², Richard J. E. Skipworth¹², Ted R. Hupp¹², J. Robert O'Neill^{12,25}, Olga Tucker^{13,31}, Philippe Taniere¹³, Jack Owsley¹⁴, Charles Crichton¹⁶, Christian Schusterreiter¹⁶, Hugh Barr¹⁷, Neil Shepherd¹⁷, Oliver Old¹⁷, Jesper Lagergren^{18,26,27}, James Gossage^{18,26}, Andrew Davies^{18,26}, Fuju Chang^{18,26}, Janine Zylstra^{18,26}, Grant Sanders¹⁹, Richard Berrisford¹⁹, Catherine Harden¹⁹, David Bunting¹⁹, Mike Lewis²⁰, Ed Cheong²⁰, Bhaskar Kumar²⁰, Simon L. Parsons²¹, Irshad Soomro²¹, Philip Kaye²¹, John Saunders²¹, Laurence Lovat²², Rehan Haidry²², Victor Eneh²², Laszlo Igali²³, Ian Welch²⁴, Michael Scott²⁴, Shamila Sothi²⁸, Sari Suortamo²⁸, Suzy Lishman²⁹, Duncan Beardsmore³⁰, Charlotte Anderson³³, Mike L. Smith³³, Maria Secrier³³, Matthew D. Eldridge³³, Lawrence Bower³³, Achilleas Achilleos³³, Andy G. Lynch³³ & Simon Tavare³³

⁴Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK. ⁵Oesophago-Gastric Unit, Addenbrooke's Hospital, Cambridge, UK. ⁶Oxford ComLab, University of Oxford, Oxford, UK. ⁷Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. ⁸Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UK. ⁹Salford Royal NHS Foundation Trust, Salford, UK. ¹⁰Wigan and Leigh NHS Foundation Trust, Wigan, Manchester, UK. ¹¹Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK. ¹²Edinburgh Royal Infirmary, Edinburgh, UK. ¹³University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. ¹⁴University Hospital Southampton NHS Foundation Trust, Southampton, UK. ¹⁵Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK. ¹⁶Department of Computer Science, University of Oxford, Oxford, UK. ¹⁷Gloucester Royal Hospital, Gloucester, UK. ¹⁸St Sharrocks's Hospital, London, UK. ¹⁹Plymouth Hospitals NHS Trust, Plymouth, UK. ²⁰Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK. ²¹Nottingham University Hospitals NHS Trust, Nottingham, UK. ²²University College London, London, UK. ²³Norfolk and Waveney Cellular Pathology Network, Norwich, UK. ²⁴Wythenshawe Hospital, Manchester, UK. ²⁵Edinburgh University, Edinburgh, UK. ²⁶King's College London, London, UK. ²⁷Karolinska Institutet, Stockholm, Sweden. ²⁸University Hospitals Coventry and Warwickshire NHS, Trust, Coventry, UK. ²⁹Peterborough Hospitals NHS Trust, Peterborough City Hospital, Peterborough, UK. ³⁰Royal Stoke University Hospital, UHNM NHS Trust, Stoke-on-Trent, UK. ³¹Institute of cancer and genomic sciences, University of Birmingham, Birmingham, UK. ³²GI science centre, University of Manchester, Manchester, UK. ³³Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.